«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年03期

页码:

309-313

栏目:

临床医学

出版日期:

2023-05-20

文章信息/Info

Title:

Expression and clinical correlation of KIF22 in clear cell renal cell carcinoma

文章编号:

1006－8147（2023）03-0309-05

作者:

张春锋¹; 李长建²; 刘沛¹; 吴春磊¹

（1.新乡医学院第一附属医院泌尿外科，卫辉 453100；2.新乡医学院第三附属医院泌尿外科，新乡 453000）

Author(s):

ZHANG Chun-feng¹; LI Chang-Jian²; LIU Pei¹; WU Chun-lei¹

（1.Department of Urology，The First Affiliated Hospital，Xinxiang Medical University，Weihui 453100，China；2.Department of Urology，The Third Affiliated Hospital，Xinxiang Medical University，Xinxiang 453000，China）

关键词:

KIF22; 肾透明细胞癌; 临床特征分析; 预后

Keywords:

KIF22; clear cell renal cell carcinoma; clinical characteristics analysis; prognosis

分类号:

R692

DOI:

-

文献标志码:

A

摘要:

目的：探讨KIF22在肾透明细胞癌中的表达情况及行根治性肾癌切除术患者临床特征与生存预后的相关性。方法：首先，使用生物信息学分析来研究KIF22在肾透明细胞癌和正常组织中的表达水平，通过Kaplan-Meier生存分析两组患者中KIF22表达水平对疾病总生存期和无进展生存期的影响。通过免疫组化染色实验分析77例肾透明细胞癌标本以及癌旁组织标本中KIF22蛋白的表达水平，根据染色强度分为高表达组、低表达组。进一步搜集患者相关临床资料进行分析比较，明确KIF22表达水平与其相关性。结果：生物信息学分析表明，KIF22在包括肾癌在内的多种癌组织中表达相对较高，Kaplan-Meier分析发现KIF22的高表达组患者有较差的疾病总生存期和无进展生存期（P=0.012、0.047）。免疫组化结果显示77例标本中，有42例标本KIF22呈高表达，35例标本呈低表达，而癌旁正常组织均呈低表达。KIF22表达水平与肿瘤大小（P=0.010）具有相关性，而与年龄性别和肿瘤分化均无关（均P>0.05）。结论：KIF22在肾透明细胞癌组织样本中异常高表达，且与肾透明细胞癌的肿瘤大小相关，并导致患者预后不良。

Abstract:

Objective： To investigate the expression of KIF22 in clear cell renal cell carcinoma and the correlation between clinical characteristics and survival prognosis of patients undergoing radical nephrectomy. Methods：First，bioinformatics analysis was used to investigate the expression levels of KIF22 in clear cell renal cell carcinoma and normal tissues.And the effect of KIF22 expression levels on overall disease survival and progression-free survival was analyzed by Kaplan-Meier survival in both groups of patients. After that，the expression levels of KIF22 protein in 77 clear cell renal cell carcinoma specimens as well as para-neoplastic tissue specimens were analyzed by immunohistochemistry（IHC） staining experiments.And they were divided into high expression group and low expression group according to the staining intensity. Further clinical data were collected for analysis and comparison to clarify the correlation with KIF22 expression level. Results：Bioinformatics analysis showed that KIF22 was relatively highly expressed in various cancer tissues，including renal cell carcinoma. Kaplan-Meier analysis revealed that patients in the high KIF22 expression group had poorer overall disease survival and progression-free survival（P=0.012，0.047）. IHC results showed that 42 of 82 specimens had high and 35 had low expression of KIF22，and the expression was low in the adjacent normal tissues. Besides，the level of KIF22 expression was correlated with tumor size（P=0.010），but not with age，sex or tumor differentiation（all P>0.05）. Conclusion：KIF22 is abnormally highly expressed in clear cell renal cell carcinoma tissue，correlated with tumor size in clear cell renal cell carcinoma and resulted in poor patient prognosis.

参考文献/References:

[1] SIEGEL R L，MILLER K D，JEMAL A. Cancer statistics[J]. CA Cancer J Clin，2018，68（1）：7-30.
[2] BRUNA F A，ROMEO L R，CAMPO-VERDE-ARBOCCO F，et al. Human renal adipose tissue from normal and tumor kidney：its influence on renal cell carcinoma[J]. Oncotarget，2019，10（52）：5454-5467.
[3] RUSSO L，AVESANI G，GUI B，et al. Immunotherapy-related imaging findings in patients with gynecological malignancies：what radiologists need to know[J]. Korean J Radiol，2021，22（8）：1310-1322.
[4] KANNO H，NAITO S，OBARA Y，et al. Effect of extracellular signal-regulated protein kinase 5 inhibition in clear cell renal cell carcinoma[J]. Int J MolSci，2022，23（15）：8448.
[5] CHAKRABORTY S，BALAN M，SABARWAL A，et al. Metabolic reprogramming in renal cancer：events of a metabolic disease[J]. Biochim Biophys Acta Rev Cancer，2021，1876（1）：188559.
[6] AIKEN J，HOLZBAUR ELF. Cytoskeletal regulation guides neuronal trafficking to effectively supply the synapse[J]. Curr Biol，2021，31（10）：R633-R650.
[7] TANG F，PAN M H，WAN X，et al. Kif18a regulates sirt2-mediated tubulin acetylation for spindle organization during mouse oocyte meiosis[J]. Cell Div，2018，13：9.
[8] DATE S S，PARKS J M，RUSH K W，et al. Kinetics of enzymatic mercury methylation at nanomolar concentrations catalyzed by HgcAB[J]. Appl Environ Microbiol，2019，85（13）：e00438-19.
[9] WU S，LI H，WANG L，et al. Motor proteins and spermatogenesis[J]. Adv Exp Med Biol，2021，1288：131-159.
[10] LI K，LI S，TANG S，et al. KIF22 promotes bladder cancer progression by activating the expression of CDCA3[J]. Int J Mol Med，2021，48（6）：211.
[11] YANG Y，GAO L，WENG N N，et al. Identification of novel molecular therapeutic targets and their potential prognostic biomarkers among kinesin superfamily of proteins in pancreatic ductal adenocarcinoma[J]. Front Oncol，2021，11：708900.
[12] GU S，LIANG H，QI D，et al. Knockdown of KIF26B inhibits breast cancer cell proliferation，migration，and invasion[J]. Onco Targets Ther，2018，11：3195-3203.
[13] KALANTARI S，FILGES I. Kinesinopathies：emerging role of the kinesin family member genes in birth defects[J]. J Med Genet，2020，57（12）：797-807.
[14] ZHANG Z，XIE H，ZHU S，et al. High expression of KIF22/kinesin-like DNA binding protein（Kid） as a poor prognostic factor in prostate cancer patients[J]. Med Sci Monit，2018，24：8190-8197.
[15] WANG K，WU Z，WANG G，et al. Survival nomogram for patients with bone metastatic renal cell carcinoma：a population-based study[J]. Int Braz J Urol，2021，47（2）：333-349.
[16] CHEN C，LIN W，HUANG Y，et al. The essential factors of establishing patient-derived tumor model[J]. J Cancer，2021，12（1）：28-37.
[17] HE L，GAO L，SHAY C，et al. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis[J].J Exp Clin Cancer Res，2019，38（1）：84.
[18] YOUNG K A，BIGGINS L，SHARPE H J. Protein tyrosine phosphatases in cell adhesion[J]. Biochem J，2021，478（5）：1061-1083.
[19] PIKE R，ORTIZ-ZAPATER E，LUMICISI B，et al. KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation[J]. Sci Signal，2018，11（515）：eaaq1060.
[20] LIU M，RAN J，ZHOU J. Non-canonical functions of the mitotic kinesin Eg5[J]. Thorac Cancer，2018，9（8）：904-910.

相似文献/References:

[1]魏诗瑶,来佳丹,李常颖.白细胞介素4诱导蛋白1促进肾癌进展的实验研究[J].天津医科大学学报,2022,28(04):366.
　WEI Shi-yao,LAI Jia-dan,LI Chang-ying.Research of interleukin-4-induced-1 promoting the progression of kidney clear cell carcinoma[J].Journal of Tianjin Medical University,2022,28(03):366.
[2]来佳丹,魏诗瑶,李常颖.肾癌来源的IL4I1介导Treg诱导与募集的实验研究[J].天津医科大学学报,2023,29(03):302.
　LAI Jia-dan,WEI Shi-yao,LI Chang-ying.Research on inducement and recruitment of Treg mediated by IL4I1 derived from renal cell carcinoma[J].Journal of Tianjin Medical University,2023,29(03):302.
[3]刘芬,李世宾,李晓石.人着丝粒蛋白E在人肾透明细胞癌中的表达及对细胞增殖的影响[J].天津医科大学学报,2023,29(06):594.
　LIU Fen,LI Shi-bin,LI Xiao-shi.Expression of human centromere protein E in human renal clear cell carcinoma and its effects on the cell proliferation[J].Journal of Tianjin Medical University,2023,29(03):594.
[4]李美,来佳丹,魏诗瑶,等.肾透明细胞癌来源的IL4I1介导PD1+CD8+ T淋巴细胞募集的相关研究[J].天津医科大学学报,2024,30(02):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]
　LI Mei,LAI Jiadan,WEI Shiyao,et al.Research on recruitment of PD1+ CD8+ T lymphocytes mediated by IL4I1 derived from clear cell renal cell carcinoma[J].Journal of Tianjin Medical University,2024,30(03):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]

备注/Memo

备注/Memo:

基金项目 新乡医学院第一附属医院博士科研基金项目（xyyfy2014BS-003）；河南省医学科技攻关计划联合共建项目（2018020350）
作者简介 张春锋（1984-），男，主治医师，硕士，研究方向：泌尿系统疾病的诊治；通信作者：吴春磊，E-mail：wuchunleiurology@foxmail.com。

常用功能

更新日期/Last Update: 1900-01-01